about
Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML.Diabetes Limits Stem Cell Mobilization Following G-CSF but Not PlerixaforMaintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.Socioeconomic status is independently associated with overall survival in patients with multiple myeloma.The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide.Personalization of cancer treatment using predictive simulationPI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance.Re: Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma.Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients.Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma.A phase I study of thymoglobulin for relapsed or refractory multiple myelomaA phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myelomaAfrican American patients may or may not have poorer response rates after monoclonal antibody treatment: Overreliance on P values in underpowered studiesMaintenance therapy following salvage autologous stem cell transplant in patients with multiple myeloma
P50
Q35525811-C198E473-26D7-4C9B-9B31-26C18D7198BAQ35881779-C2637AF1-5FCB-48A5-9ED8-8A3BDE0CD299Q36055095-17E00E7B-E1E4-4F3D-B154-66180624E064Q36797000-88360703-8769-4EFE-9D4D-F59B85D1A7EBQ37633986-F05CB3AA-EE3D-4F04-AB77-5E70D45CEE2AQ38914605-20C74AFA-3857-4712-A10A-3DBB1CD37F20Q39036088-280EBE18-83D2-43A7-9ADE-BF122685933FQ41222600-B945C20C-7C39-424B-BB6D-5D727A157058Q43671151-F2673E7C-E1FD-4F1D-8E6E-17E48806488EQ47563557-A557E367-D352-43EB-81AE-E703C776A842Q87304760-D753E484-B49A-4FBA-869A-4912F76B41FBQ87455016-92553291-99F3-42E6-BE8C-1176C2D40F13Q92665534-E1F962FB-B10C-4833-9198-BBB0C51DF602Q92965521-12E7B53E-A408-44BC-A22D-4757E9F5C1A9
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
研究者
@zh
name
Mark A Fiala
@ast
Mark A Fiala
@en
Mark A Fiala
@es
Mark A Fiala
@nl
type
label
Mark A Fiala
@ast
Mark A Fiala
@en
Mark A Fiala
@es
Mark A Fiala
@nl
prefLabel
Mark A Fiala
@ast
Mark A Fiala
@en
Mark A Fiala
@es
Mark A Fiala
@nl
P31
P496
0000-0002-0208-5023